Intra-cellular therapies, inc. (ITCI)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Sep'12
Revenue

0

-

-

-

-

-

-

-

-

245

245

442

0

-

0

0

-

91

126

250

412

577

1,338

1,882

2,306

2,737

2,287

0

0

0

Operating expenses:
Cost of product sales

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

80,137

89,124

103,664

117,743

126,454

132,166

125,490

108,543

88,583

79,419

73,668

79,114

91,936

93,831

95,518

100,057

92,519

87,718

76,493

52,082

37,029

21,226

15,715

15,826

20,904

23,027

18,695

0

0

0

Selling, general and administrative

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

51,201

44,137

-

30,099

26,866

24,212

23,737

23,666

24,834

25,787

26,004

24,758

24,344

21,965

19,479

18,187

15,371

14,061

12,196

10,337

9,346

8,060

6,842

5,976

4,047

0

0

0

Total operating expenses

167,545

154,072

154,866

161,881

161,878

162,266

152,357

132,755

112,320

103,085

98,503

104,901

117,941

118,589

119,862

122,023

111,999

105,905

91,864

66,143

49,225

31,564

25,061

23,886

27,747

29,003

22,742

0

0

0

Loss from operations

-166,401

-154,011

-154,866

-161,881

-161,878

-162,266

-152,352

-132,719

-112,170

-102,840

-98,164

-104,589

-117,515

-118,258

-119,599

-121,764

-111,911

-105,813

-91,738

-65,892

-48,813

-30,986

-23,722

-22,004

-25,440

-26,266

-20,455

0

0

0

Interest income

6,109

6,291

6,980

7,334

7,396

7,140

6,707

5,723

4,787

4,005

3,369

3,249

3,100

2,935

2,669

2,094

1,564

1,022

581

481

381

303

222

139

62

29

18

0

0

0

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

7

15

146

376

612

0

0

0

-

Loss before provision for income taxes

-160,292

-147,720

-147,885

-154,546

-154,481

-155,125

-145,644

-126,996

-107,382

-98,834

-94,819

-101,377

-114,451

-115,360

-120,269

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

Income tax expense

0

-

-

0

-

-

-

0

-

-1,060

830

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Net loss

-160,297

-147,722

-147,887

-154,547

-154,483

-155,127

-144,588

-125,935

-106,319

-97,773

-95,049

-102,444

-115,518

-116,426

-117,775

-119,670

-110,347

-104,793

-91,157

-65,412

-48,435

-30,691

-23,533

-22,029

-25,773

-26,868

-21,050

0

0

0

Net loss per common share:
Basic & Diluted

-0.73

-0.74

-0.63

-0.68

-0.63

-0.75

-0.76

-0.68

-0.65

-0.56

-0.53

-0.41

-0.62

-0.64

-0.70

-0.71

-0.64

-0.67

-0.91

-0.61

-0.72

-0.53

-0.22

-0.15

-0.17

-0.33

-0.28

-0.56

-0.39

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.40

Dilutive

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.40

Weighted average number of common shares:
Basic & Diluted

65,106

55,278

55,207

55,145

55,113

54,750

54,708

54,696

54,676

54,497

43,424

43,419

43,385

43,273

43,253

43,239

43,193

43,178

35,320

35,002

30,775

29,471

29,379

29,273

26,475

22,224

17,527

14,690

14,599

5,607

Product sales, net [Member]
Revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Grant revenue [Member]
Revenue

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-